Already a member? Sign in
Levetiracetam is is an anticonvulsant used in combination with other medications to treat partial onset, myoclonic, and/or primary generalized tonic-clonic seizures.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Epilepsy | 700 | 284 |
|
|
|
|
|
| Seizures | 55 | 11 |
|
|
|
|
|
| Seizures (grand mal or tonic-clonic) | 42 | 23 |
|
|
|
|
|
| Seizures (complex partial) | 36 | 17 |
|
|
|
|
|
| Other | 30 | 4 |
|
|
|
|
|
| Seizures (partial focal) | 17 | 3 |
|
|
|
See all 869 patients currently taking Levetiracetam
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Levetiracetam
| Fatigue | 31 | |
|---|---|---|
| Sleepiness | 20 | |
| Excessive daytime sleepiness (somnolence) | 17 | |
| Memory problems | 16 | |
| Dizziness | 15 | |
| Depressed mood | 14 | |
| See all 201 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Levetiracetam. See all 65 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 102 | ||
| Did not seem to work | 70 | ||
| Doctor's advice | 59 | ||
| Other | 24 | ||
| Expense | 17 | ||
| Course of treatment ended | 11 | ||
| Personal research | 8 | ||
| Not indicated | 6 | ||
| Change in health plan coverage | 4 |
Adherence
Taking treatment as prescribed
Adherence of Levetiracetam
Always |
315 | 89% |
|
|---|---|---|---|
Usually |
30 | 8% |
|
Sometimes |
3 | 1% |
|
Never |
7 | 2% |
|
Burden
Difficulty being on treatment
Burden of Levetiracetam
Very |
23 | 6% |
|
|---|---|---|---|
Somewhat |
34 | 10% |
|
A little |
58 | 16% |
|
Not at all |
240 | 68% |
|
Cost
Paid out of pocket
Cost of Levetiracetam
$200+ |
15 | 7% |
|
|---|---|---|---|
$100-199 |
12 | 5% |
|
$50-99 |
33 | 14% |
|
$25-49 |
27 | 12% |
|
< $25 |
140 | 61% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 11, 2012.